The FY 23' Omnibus bill has landed and it has major implications for FDA enforcement towards medical device product security.
With an implementation date pushed back to October 1, 2023, the FDA is tightening the reigns on medical device manufacturers. We relied on first-hand research, interviews, and public documents to extract what the FDA and their focus on SBOMS means for
Medical device manufacturers.
Watch this webinar to learn about:
- The FDA’s approach to cybersecurity
- Trustworthiness and transparency
- Ecosystem and device resilience
We'll dive into:
How SBOMs will act as a means of maintaining vendor and customer transparency
The need to scale SBOM management, vulnerability management, policy approval, and more
Shifting responsibilities to ensure post-market requirements, during premarket development